Featured Research

from universities, journals, and other organizations

Patient-specific vaccines for metastatic melanoma may induce durable complete regression, study shows

Date:
September 27, 2010
Source:
Hoag Memorial Hospital Presbyterian
Summary:
Researchers have announced encouraging clinical study results for patient-specific vaccine therapy to treat metastatic melanoma. The study is ongoing, but the report concludes that patient-specific vaccines can sometimes induce durable complete regression of progressing soft-tissue melanoma metastases, as demonstrated in one particular patient who participated in the trial.

Hoag Memorial Hospital Presbyterian recently announced encouraging clinical study results for patient-specific vaccine therapy to treat metastatic melanoma. The study is ongoing, but the report concludes that patient-specific vaccines can sometimes induce durable complete regression of progressing soft-tissue melanoma metastases, as demonstrated in one particular patient who participated in the trial.

Related Articles


The study report, entitled: "Durable Complete Response of Refractory, Progressing, Metastatic Melanoma after Treatment with a Patient-Specific Vaccine," will appear in the October issue of Cancer Biotherapy and Radiopharmaceuticals. Lead author on the report is Robert O. Dillman, MD, FACP, medical oncologist and cancer immunologist, as well as executive medical and scientific director at Hoag Cancer Institute. The study was sponsored by Hoag Hospital Foundation.

"Although we had previously shown that patient-specific vaccines can be associated with long-term disease control and survival despite previous recurrences of widespread metastatic melanoma, 1,2,3 this is the first complete regression we have observed with a dendritic cell-based patient-specific vaccine therapy in patients with measurable metastatic melanoma," said Dr. Dillman.

The patient profiled in the study presented with cervical spine metastases and within the year had experienced local disease progression and, despite various therapies, metastases to the axilla, rectum, gall bladder, and multiple soft-tissue sites. She had previously received radiation therapy, combination chemotherapy, interleukin-2 plus interferon biotherapy, gamma knife radiosurgery, and undergone multiple surgical resections. At the time vaccine therapy was initiated, she had multiple new, measurable, soft-tissue metastases that were increasing in size.

The patient was treated with a vaccine consisting of autologous dendritic cells incubated with irradiated tumor cells from an autologous tumor cell line and suspended in GM-CSF, with s.c. injections once a week for three weeks and monthly for five months. There was evidence of disease regression by the completion of therapy. A few months later, a complete response was documented by radiologic scans, and subsequently reconfirmed at six-month intervals. She remains in complete remission more than 2.5 years after starting the vaccine, and more than 2 years after completing the vaccine, and survives more than four years after her initial presentation with bone, bowel, and lymph node metastases. This is the first time she has been in a complete remission since her initial diagnosis.

"These results are extremely encouraging for patients suffering from metastatic melanoma," said Dr. Dillman. "The promise of new therapies such as personalized cancer vaccines may help contribute to survival rates in these patients."


Story Source:

The above story is based on materials provided by Hoag Memorial Hospital Presbyterian. Note: Materials may be edited for content and length.


Journal References:

  1. Robert O. Dillman, Carol DePriest, Cristina DeLeon, Neil M. Barth, Lee S. Schwartzberg, Linda D. Beutel, Patric M. Schiltz, Shankar K. Nayak. Patient-Specific Vaccines Derived from Autologous Tumor Cell Lines as Active Specific Immunotherapy: Results of Exploratory Phase I/II Trials in Patients with Metastatic Melanoma. Cancer Biotherapy & Radiopharmaceuticals, 2007; 22 (3): 309 DOI: 10.1089/cbr.2007.345
  2. Robert O. Dillman, Senthamil R. Selvan, Patric M. Schiltz. Patient-Specific Dendritic-Cell Vaccines for Metastatic Melanoma. New England Journal of Medicine, 2006; 355 (11): 1179 DOI: 10.1056/NEJMc061667
  3. Robert O. Dillman, Senthamil R. Selvan, Patric M. Schiltz, Edward F. McClay, Neil M. Barth, Carol DePriest, Cristina de Leon, Cheryl Mayorga, Andrew N. Cornforth, Kanoe Allen. Phase II Trial of Dendritic Cells Loaded with Antigens from Self-Renewing, Proliferating Autologous Tumor Cells as Patient-Specific Antitumor Vaccines in Patients with Metastatic Melanoma: Final Report. Cancer Biotherapy & Radiopharmaceuticals, 2009; 24 (3): 311 DOI: 10.1089/cbr.2008.0599
  4. Robert O. Dillman, Andreea A. Nanci, Scott T. Williams, Richard B. Kim, Russell L. Hafer, Colleen L. Coleman, Peter C. Wang, Christopher M. Duma, Peter V. Chen, Senthamil R. Selvan, Andrew N. Cornforth, Carol DePriest. Durable Complete Response of Refractory, Progressing Metastatic Melanoma After Treatment with a Patient-Specific Vaccine. Cancer Biotherapy & Radiopharmaceuticals, 2010; 100919063940021 DOI: 10.1089/cbr.2010.0819

Cite This Page:

Hoag Memorial Hospital Presbyterian. "Patient-specific vaccines for metastatic melanoma may induce durable complete regression, study shows." ScienceDaily. ScienceDaily, 27 September 2010. <www.sciencedaily.com/releases/2010/09/100927112948.htm>.
Hoag Memorial Hospital Presbyterian. (2010, September 27). Patient-specific vaccines for metastatic melanoma may induce durable complete regression, study shows. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2010/09/100927112948.htm
Hoag Memorial Hospital Presbyterian. "Patient-specific vaccines for metastatic melanoma may induce durable complete regression, study shows." ScienceDaily. www.sciencedaily.com/releases/2010/09/100927112948.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins